DrugsControl Media Services
DrugsControl.org

News Detail

Zydus, CSIR-CDRI Lucknow to develop drug for CKD-induced postmenopausal Osteoporosis (02-10-2024)

New Delhi, 01 Oct 2024: Based on research conducted at Central Drug Research Institute (CDRI), Lucknow and data from antibody-based therapies (biologics), a protein Sclerostin, has emerged as a promising drug target for treating Chronic kidney disease (CKD) induced osteoporosis a......
View Details

Source : PIB
CDRI antibody-based therapies (biologics) protein Sclerostin Chronic kidney disease (CKD) postmenopausal osteoporosis

Related News